Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

Yes, lung cancer can be curable — if it’s found early and responds well to treatment. Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved.

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

Investing.com -- BeyondSpring Inc (NASDAQ:BYSI) shares gained 4.6% in premarket trading Friday following the company’s announcement of positive results from the Asian subset of its Phase 3 DUBLIN-3 ...

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the ...